This report contains market size and forecasts of Malignant Mesothelioma Therapeutic in Global, including the following market information:
Global Malignant Mesothelioma Therapeutic Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Malignant Mesothelioma Therapeutic market was valued at 317.7 million in 2020 and is projected to reach US$ 411.8 million by 2027, at a CAGR of 6.7% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Malignant Mesothelioma Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Malignant Mesothelioma Therapeutic Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Malignant Mesothelioma Therapeutic Market Segment Percentages, By Type, 2020 (%)
Pemetrexed
Cisplatin
Others
China Malignant Mesothelioma Therapeutic Market, By Application, 2016-2021, 2022-2027 ($ millions)
China Malignant Mesothelioma Therapeutic Market Segment Percentages, By Application, 2020 (%)
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
Global Malignant Mesothelioma Therapeutic Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global Malignant Mesothelioma Therapeutic Market Segment Percentages, By Region and Country, 2020 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Total Malignant Mesothelioma Therapeutic Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Malignant Mesothelioma Therapeutic Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Malignant Mesothelioma Therapeutic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Malignant Mesothelioma Therapeutic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Malignant Mesothelioma Therapeutic Overall Market Size
2.1 Global Malignant Mesothelioma Therapeutic Market Size: 2021 VS 2027
2.2 Global Malignant Mesothelioma Therapeutic Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Malignant Mesothelioma Therapeutic Players in Global Market
3.2 Top Global Malignant Mesothelioma Therapeutic Companies Ranked by Revenue
3.3 Global Malignant Mesothelioma Therapeutic Revenue by Companies
3.4 Top 3 and Top 5 Malignant Mesothelioma Therapeutic Companies in Global Market, by Revenue in 2020
3.5 Global Companies Malignant Mesothelioma Therapeutic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Malignant Mesothelioma Therapeutic Players in Global Market
3.6.1 List of Global Tier 1 Malignant Mesothelioma Therapeutic Companies
3.6.2 List of Global Tier 2 and Tier 3 Malignant Mesothelioma Therapeutic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Malignant Mesothelioma Therapeutic Market Size Markets, 2021 & 2027
4.1.2 Pemetrexed
4.1.3 Cisplatin
4.1.4 Others
4.2 By Type - Global Malignant Mesothelioma Therapeutic Revenue & Forecasts
4.2.1 By Type - Global Malignant Mesothelioma Therapeutic Revenue, 2016-2021
4.2.2 By Type - Global Malignant Mesothelioma Therapeutic Revenue, 2022-2027
4.2.3 By Type - Global Malignant Mesothelioma Therapeutic Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Malignant Mesothelioma Therapeutic Market Size, 2021 & 2027
5.1.2 Pleural Mesothelioma
5.1.3 Peritoneal Mesothelioma
5.1.4 Others
5.2 By Application - Global Malignant Mesothelioma Therapeutic Revenue & Forecasts
5.2.1 By Application - Global Malignant Mesothelioma Therapeutic Revenue, 2016-2021
5.2.2 By Application - Global Malignant Mesothelioma Therapeutic Revenue, 2022-2027
5.2.3 By Application - Global Malignant Mesothelioma Therapeutic Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Malignant Mesothelioma Therapeutic Market Size, 2021 & 2027
6.2 By Region - Global Malignant Mesothelioma Therapeutic Revenue & Forecasts
6.2.1 By Region - Global Malignant Mesothelioma Therapeutic Revenue, 2016-2021
6.2.2 By Region - Global Malignant Mesothelioma Therapeutic Revenue, 2022-2027
6.2.3 By Region - Global Malignant Mesothelioma Therapeutic Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Malignant Mesothelioma Therapeutic Revenue, 2016-2027
6.3.2 US Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.3.3 Canada Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.3.4 Mexico Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Malignant Mesothelioma Therapeutic Revenue, 2016-2027
6.4.2 Germany Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.4.3 France Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.4.4 U.K. Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.4.5 Italy Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.4.6 Russia Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.4.7 Nordic Countries Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.4.8 Benelux Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Malignant Mesothelioma Therapeutic Revenue, 2016-2027
6.5.2 China Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.5.3 Japan Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.5.4 South Korea Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.5.5 Southeast Asia Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.5.6 India Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Malignant Mesothelioma Therapeutic Revenue, 2016-2027
6.6.2 Brazil Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.6.3 Argentina Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Malignant Mesothelioma Therapeutic Revenue, 2016-2027
6.7.2 Turkey Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.7.3 Israel Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.7.4 Saudi Arabia Malignant Mesothelioma Therapeutic Market Size, 2016-2027
6.7.5 UAE Malignant Mesothelioma Therapeutic Market Size, 2016-2027
7 Players Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Corporate Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Major Product Offerings
7.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.1.5 Eli Lilly Key News
7.2 Teva
7.2.1 Teva Corporate Summary
7.2.2 Teva Business Overview
7.2.3 Teva Malignant Mesothelioma Therapeutic Major Product Offerings
7.2.4 Teva Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.2.5 Teva Key News
7.3 Sanofi
7.3.1 Sanofi Corporate Summary
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Malignant Mesothelioma Therapeutic Major Product Offerings
7.3.4 Sanofi Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.3.5 Sanofi Key News
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Corporate Summary
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Major Product Offerings
7.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.4.5 Bristol-Myers Squibb Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Malignant Mesothelioma Therapeutic Major Product Offerings
7.5.4 Pfizer Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.5.5 Pfizer Key News
7.6 Roche
7.6.1 Roche Corporate Summary
7.6.2 Roche Business Overview
7.6.3 Roche Malignant Mesothelioma Therapeutic Major Product Offerings
7.6.4 Roche Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.6.5 Roche Key News
7.7 Merck
7.7.1 Merck Corporate Summary
7.7.2 Merck Business Overview
7.7.3 Merck Malignant Mesothelioma Therapeutic Major Product Offerings
7.4.4 Merck Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.7.5 Merck Key News
7.8 Ono Pharmaceutical
7.8.1 Ono Pharmaceutical Corporate Summary
7.8.2 Ono Pharmaceutical Business Overview
7.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Major Product Offerings
7.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.8.5 Ono Pharmaceutical Key News
7.9 Mylan
7.9.1 Mylan Corporate Summary
7.9.2 Mylan Business Overview
7.9.3 Mylan Malignant Mesothelioma Therapeutic Major Product Offerings
7.9.4 Mylan Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.9.5 Mylan Key News
7.10 Fresenius Kabi
7.10.1 Fresenius Kabi Corporate Summary
7.10.2 Fresenius Kabi Business Overview
7.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Major Product Offerings
7.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.10.5 Fresenius Kabi Key News
7.11 Sun Pharmaceuticals
7.11.1 Sun Pharmaceuticals Corporate Summary
7.11.2 Sun Pharmaceuticals Business Overview
7.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Major Product Offerings
7.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue in Global (2016-2021)
7.11.5 Sun Pharmaceuticals Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Malignant Mesothelioma Therapeutic Market Opportunities & Trends in Global Market
Table 2. Malignant Mesothelioma Therapeutic Market Drivers in Global Market
Table 3. Malignant Mesothelioma Therapeutic Market Restraints in Global Market
Table 4. Key Players of Malignant Mesothelioma Therapeutic in Global Market
Table 5. Top Malignant Mesothelioma Therapeutic Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Malignant Mesothelioma Therapeutic Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Malignant Mesothelioma Therapeutic Revenue Share by Companies, 2016-2021
Table 8. Global Companies Malignant Mesothelioma Therapeutic Product Type
Table 9. List of Global Tier 1 Malignant Mesothelioma Therapeutic Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Malignant Mesothelioma Therapeutic Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals